Artiva Biotherapeutics (ARTV) Accounts Payables (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Accounts Payables data on file, last reported at $2.3 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 12.28% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 12.28% increase from a year earlier, with the FY2025 full-year figure at $355000.0, down 68.33% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.3 million, up from $355000.0 in the prior quarter.
• Over the last five years, Accounts Payables for ARTV reached as high as $2.3 million in Q1 2026 and fell as low as $355000.0 in Q4 2025.
• Historically, Accounts Payables has averaged $1.2 million across 4 years, with a median of $1.1 million in 2024.
• Across the five-year window, Accounts Payables surged 82.57% in 2024 and sank 68.33% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $614000.0 in 2023, then soared by 82.57% to $1.1 million in 2024, then sank by 68.33% to $355000.0 in 2025, then jumped by 543.94% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $2.3 million in Q1 2026, $355000.0 in Q4 2025, and $848000.0 in Q3 2025.